Companies Cryptocurrencies
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Exchange: Nasdaq Global Select
IPO Date: 03/03/2016
CEO: Dr. Briggs Morrison
Biotechnology Healthcare 🔗
  • SNDX
  • 14.63
  • 822678528
    market cap
  • 0.60999966
If you bought

shares of Syndax Pharmaceuticals Inc (SNDX) on
You would have made
Old Price $12 Current Price $12

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 38 full-time employees. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. The company is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

Address: Building D 35 Gatehouse Dr Fl 3 Waltham MASSACHUSETTS 02451

Stay updated.